Arbutus Biopharma Corp (ABUS)
NASDAQ·Healthcare·Biotechnology
$3.60
-1.50%
Mkt Cap $804.31M
Analyst Ratings
No recent rating data.
Price Target (1 analysts)
$8.50
Range $8.50 – $8.50
Implied Upside
+136.1%
Consensus $8.50 vs current $3.60
NASDAQ·Healthcare·Biotechnology
$3.60
-1.50%
Mkt Cap $804.31M
No recent rating data.
Price Target (1 analysts)
$8.50
Range $8.50 – $8.50
+136.1%
Consensus $8.50 vs current $3.60